Literature DB >> 3132199

Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour.

P M Mannucci, A R Zanetti, M Colombo.   

Abstract

A factor VIII concentrate prepared from large plasma pools and then exposed to hot vapour to inactivate blood-borne viruses was evaluated in 28 factor-VIII deficient patients (14 vaccinated against the hepatitis B virus, HBV) who had not been treated with any blood product and hence were highly susceptible to the development of post-transfusion hepatitis. Tests for aminotransferases and HBV markers were made every 2 weeks in the first 4 months and at 5, 6 and 12 months. Twenty-four patients were considered not to have developed hepatitis, either because they had no elevations of aminotransferases or did not become seropositive for HBV markers. The four remaining unvaccinated patients (three treated with the same batch and the fourth with a different one) developed HBV infection 8-24 weeks after the first concentrate infusion. Hence, this method of viral inactivation did not afford complete protection from hepatitis B.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132199     DOI: 10.1111/j.1365-2141.1988.tb04230.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Safety trial of heated factor VIII concentrate (8Y).

Authors:  K J Pasi; F G Hill
Journal:  Arch Dis Child       Date:  1989-10       Impact factor: 3.791

2.  In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. The influence of reagents and standards.

Authors:  M Köhler; E Seifried; P Hellstern; G Pindur; C Miyashita; S Mörsdorf; F Fasco; E Wenzel
Journal:  Blut       Date:  1988-12

Review 3.  Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.

Authors:  Robert Klamroth; Albrecht Gröner; Toby L Simon
Journal:  Transfusion       Date:  2013-09-30       Impact factor: 3.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.